Skip to main content
Erschienen in: European Journal of Epidemiology 7/2023

12.05.2023 | CANCER

Lipidomics and pancreatic cancer risk in two prospective studies

verfasst von: Sabine Naudin, Joshua N. Sampson, Steven C. Moore, Demetrius Albanes, Neal D. Freedman, Stephanie J. Weinstein, Rachael Stolzenberg-Solomon

Erschienen in: European Journal of Epidemiology | Ausgabe 7/2023

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic ductal carcinoma (PDAC) is highly fatal with limited understanding of mechanisms underlying its carcinogenesis. We comprehensively investigated whether lipidomic measures were associated with PDAC in two prospective studies. We measured 904 lipid species and 252 fatty acids across 15 lipid classes in pre-diagnostic serum (up to 24 years) in a PDAC nested-case control study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO, NCT00002540) with 332 matched case–control sets including 272 having serial blood samples and Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC, NCT00342992) with 374 matched case–control sets. Controls were matched to cases by cohort, age, sex, race, and date at blood draw. We used conditional logistic regression to calculate odds ratios (OR) and 95% confidence intervals (CI) per one-standard deviation increase in log-lipid concentrations within each cohort, and combined ORs using fixed-effects meta-analyses. Forty-three lipid species were associated with PDAC (false discovery rate, FDR ≤ 0.10), including lysophosphatidylcholines (LPC, n = 2), phosphatidylethanolamines (PE, n = 17), triacylglycerols (n = 13), phosphatidylcholines (PC, n = 3), diacylglycerols (n = 4), monoacylglycerols (MAG, n = 2), cholesteryl esters (CE, n = 1), and sphingomyelins (n = 1). LPC(18:2) and PE(O-16:0/18:2) showed significant inverse associations with PDAC at the Bonferroni threshold (P value < 5.5 × 10–5). The fatty acids LPC[18:2], LPC[16:0], PC[15:0], MAG[18:1] and CE[22:0] were significantly associated with PDAC (FDR < 0.10). Similar associations were observed in both cohorts. There was no significant association for the differences between PLCO serial lipidomic measures or heterogeneity by follow-up time overall. Results support that the pre-diagnostic serum lipidome, including 43 lipid species from 8 lipid classes and 5 fatty acids, is associated with PDAC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.PubMedCrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.PubMedCrossRef
4.
Zurück zum Zitat Gordon-Dseagu VL, Devesa SS, Goggins M, Stolzenberg-Solomon R. Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. Int J Epidemiol. 2018;47:427–39.PubMedCrossRef Gordon-Dseagu VL, Devesa SS, Goggins M, Stolzenberg-Solomon R. Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. Int J Epidemiol. 2018;47:427–39.PubMedCrossRef
5.
Zurück zum Zitat Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114–7.PubMedPubMedCentralCrossRef Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114–7.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Wang R, Li B, Lam SM, Shui G. Integration of lipidomics and metabolomics for in-depth understanding of cellular mechanism and disease progression. J Genet Genom Yi Chuan Xue Bao. 2020;47:69–83.CrossRef Wang R, Li B, Lam SM, Shui G. Integration of lipidomics and metabolomics for in-depth understanding of cellular mechanism and disease progression. J Genet Genom Yi Chuan Xue Bao. 2020;47:69–83.CrossRef
8.
Zurück zum Zitat Heimerl S, Fischer M, Baessler A, Liebisch G, Sigruener A, Wallner S, et al. Alterations of plasma lysophosphatidylcholine species in obesity and weight loss. PLoS ONE. 2014;9: e111348.PubMedPubMedCentralCrossRef Heimerl S, Fischer M, Baessler A, Liebisch G, Sigruener A, Wallner S, et al. Alterations of plasma lysophosphatidylcholine species in obesity and weight loss. PLoS ONE. 2014;9: e111348.PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Fernandez C, Surma MA, Klose C, Gerl MJ, Ottosson F, Ericson U, et al. Plasma lipidome and prediction of type 2 diabetes in the population-based Malmö diet and cancer cohort. Diabetes Care. 2020;43:366–73.PubMedCrossRef Fernandez C, Surma MA, Klose C, Gerl MJ, Ottosson F, Ericson U, et al. Plasma lipidome and prediction of type 2 diabetes in the population-based Malmö diet and cancer cohort. Diabetes Care. 2020;43:366–73.PubMedCrossRef
10.
Zurück zum Zitat Eichelmann F, Sellem L, Wittenbecher C, Jäger S, Kuxhaus O, Prada M, et al. Deep lipidomics in human plasma—cardiometabolic disease risk and effect of dietary fat modulation. Circulation. 2022;146:21–35.PubMedCrossRef Eichelmann F, Sellem L, Wittenbecher C, Jäger S, Kuxhaus O, Prada M, et al. Deep lipidomics in human plasma—cardiometabolic disease risk and effect of dietary fat modulation. Circulation. 2022;146:21–35.PubMedCrossRef
11.
Zurück zum Zitat Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18:493–592.PubMedPubMedCentralCrossRef Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18:493–592.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat WCRF/AICR. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report 2018. Alcoholic drinks and the risk of cancer [Internet]. WCRF/AICR; 2018. dietandcancerreport.org. WCRF/AICR. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report 2018. Alcoholic drinks and the risk of cancer [Internet]. WCRF/AICR; 2018. dietandcancerreport.org.
13.
Zurück zum Zitat Thiébaut ACM, Jiao L, Silverman DT, Cross AJ, Thompson FE, Subar AF, et al. Dietary fatty acids and pancreatic cancer in the NIH-AARP diet and health study. J Natl Cancer Inst. 2009;101:1001–11.PubMedPubMedCentralCrossRef Thiébaut ACM, Jiao L, Silverman DT, Cross AJ, Thompson FE, Subar AF, et al. Dietary fatty acids and pancreatic cancer in the NIH-AARP diet and health study. J Natl Cancer Inst. 2009;101:1001–11.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Zhou D, Mu D, Cheng M, Dou Y, Zhang X, Feng Z, et al. Differences in lipidomics may be potential biomarkers for early diagnosis of pancreatic cancer. Acta Cir Bras. 2020;35: e202000508.PubMedPubMedCentralCrossRef Zhou D, Mu D, Cheng M, Dou Y, Zhang X, Feng Z, et al. Differences in lipidomics may be potential biomarkers for early diagnosis of pancreatic cancer. Acta Cir Bras. 2020;35: e202000508.PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Gaiser RA, Pessia A, Ateeb Z, Davanian H, Fernández Moro C, Alkharaan H, et al. Integrated targeted metabolomic and lipidomic analysis: a novel approach to classifying early cystic precursors to invasive pancreatic cancer. Sci Rep. 2019;9:10208.PubMedPubMedCentralCrossRef Gaiser RA, Pessia A, Ateeb Z, Davanian H, Fernández Moro C, Alkharaan H, et al. Integrated targeted metabolomic and lipidomic analysis: a novel approach to classifying early cystic precursors to invasive pancreatic cancer. Sci Rep. 2019;9:10208.PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Tao L, Zhou J, Yuan C, Zhang L, Li D, Si D, et al. Metabolomics identifies serum and exosomes metabolite markers of pancreatic cancer. Metabol Off J Metab Soc. 2019;15:86. Tao L, Zhou J, Yuan C, Zhang L, Li D, Si D, et al. Metabolomics identifies serum and exosomes metabolite markers of pancreatic cancer. Metabol Off J Metab Soc. 2019;15:86.
17.
Zurück zum Zitat Wolrab D, Jirásko R, Cífková E, Höring M, Mei D, Chocholoušková M, et al. Lipidomic profiling of human serum enables detection of pancreatic cancer. Nat Commun. 2022;13:124.PubMedPubMedCentralCrossRef Wolrab D, Jirásko R, Cífková E, Höring M, Mei D, Chocholoušková M, et al. Lipidomic profiling of human serum enables detection of pancreatic cancer. Nat Commun. 2022;13:124.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Ann Epidemiol. 1994;4:1–10. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Ann Epidemiol. 1994;4:1–10.
19.
Zurück zum Zitat Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21:273S-309S.PubMedCrossRef Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21:273S-309S.PubMedCrossRef
20.
Zurück zum Zitat Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125–32.PubMedPubMedCentralCrossRef Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125–32.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Korhonen P, Malila N, Pukkala E, Teppo L, Albanes D, Virtamo J. The Finnish Cancer Registry as follow-up source of a large trial cohort–accuracy and delay. Acta Oncol Stockh Swed. 2002;41:381–8.CrossRef Korhonen P, Malila N, Pukkala E, Teppo L, Albanes D, Virtamo J. The Finnish Cancer Registry as follow-up source of a large trial cohort–accuracy and delay. Acta Oncol Stockh Swed. 2002;41:381–8.CrossRef
22.
Zurück zum Zitat Löfgren L, Ståhlman M, Forsberg G-B, Saarinen S, Nilsson R, Hansson GI. The BUME method: a novel automated chloroform-free 96-well total lipid extraction method for blood plasma. J Lipid Res. 2012;53:1690–700.PubMedCentralCrossRef Löfgren L, Ståhlman M, Forsberg G-B, Saarinen S, Nilsson R, Hansson GI. The BUME method: a novel automated chloroform-free 96-well total lipid extraction method for blood plasma. J Lipid Res. 2012;53:1690–700.PubMedCentralCrossRef
23.
Zurück zum Zitat Fay MP, Graubard BI, Freedman LS, Midthune DN. Conditional logistic regression with sandwich estimators: application to a meta-analysis. Biometrics. 1998;54:195–208.PubMedCrossRef Fay MP, Graubard BI, Freedman LS, Midthune DN. Conditional logistic regression with sandwich estimators: application to a meta-analysis. Biometrics. 1998;54:195–208.PubMedCrossRef
25.
Zurück zum Zitat Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125:279–84.PubMedCrossRef Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125:279–84.PubMedCrossRef
27.
Zurück zum Zitat Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc Ser B Methodol. 1996;58:267–88. Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc Ser B Methodol. 1996;58:267–88.
29.
Zurück zum Zitat Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):22.CrossRef Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):22.CrossRef
30.
Zurück zum Zitat Yuan C, Kim J, Wang QL, Lee AA, Babic A, PanScan/PanC4 I-III Consortium, et al. The age-dependent association of risk factors with pancreatic cancer. Ann Oncol Off J Eur Soc Med Oncol. 2022;33:693–701.CrossRef Yuan C, Kim J, Wang QL, Lee AA, Babic A, PanScan/PanC4 I-III Consortium, et al. The age-dependent association of risk factors with pancreatic cancer. Ann Oncol Off J Eur Soc Med Oncol. 2022;33:693–701.CrossRef
31.
Zurück zum Zitat Klein AP, Wolpin BM, Risch HA, Stolzenberg-Solomon RZ, Mocci E, Zhang M, et al. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nat Commun. 2018;9:556.PubMedPubMedCentralCrossRef Klein AP, Wolpin BM, Risch HA, Stolzenberg-Solomon RZ, Mocci E, Zhang M, et al. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nat Commun. 2018;9:556.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Martín-Blázquez A, Jiménez-Luna C, Díaz C, Martínez-Galán J, Prados J, Vicente F, et al. Discovery of pancreatic adenocarcinoma biomarkers by untargeted metabolomics. Cancers. 2020;12:1002.PubMedPubMedCentralCrossRef Martín-Blázquez A, Jiménez-Luna C, Díaz C, Martínez-Galán J, Prados J, Vicente F, et al. Discovery of pancreatic adenocarcinoma biomarkers by untargeted metabolomics. Cancers. 2020;12:1002.PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Ritchie SA, Akita H, Takemasa I, Eguchi H, Pastural E, Nagano H, et al. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer. 2013;13:416.PubMedPubMedCentralCrossRef Ritchie SA, Akita H, Takemasa I, Eguchi H, Pastural E, Nagano H, et al. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer. 2013;13:416.PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Urayama S, Zou W, Brooks K, Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun Mass Spectrom RCM. 2010;24:613–20.PubMedCrossRef Urayama S, Zou W, Brooks K, Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun Mass Spectrom RCM. 2010;24:613–20.PubMedCrossRef
36.
Zurück zum Zitat Mehta KY, Wu H-J, Menon SS, Fallah Y, Zhong X, Rizk N, et al. Metabolomic biomarkers of pancreatic cancer: a meta-analysis study. Oncotarget. 2017;8:68899–915.PubMedPubMedCentralCrossRef Mehta KY, Wu H-J, Menon SS, Fallah Y, Zhong X, Rizk N, et al. Metabolomic biomarkers of pancreatic cancer: a meta-analysis study. Oncotarget. 2017;8:68899–915.PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Di Gangi IM, Mazza T, Fontana A, Copetti M, Fusilli C, Ippolito A, et al. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites. Oncotarget. 2016;7:5815–29.PubMedPubMedCentralCrossRef Di Gangi IM, Mazza T, Fontana A, Copetti M, Fusilli C, Ippolito A, et al. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites. Oncotarget. 2016;7:5815–29.PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Liu P, Zhu W, Chen C, Yan B, Zhu L, Chen X, et al. The mechanisms of lysophosphatidylcholine in the development of diseases. Life Sci. 2020;247: 117443.PubMedCrossRef Liu P, Zhu W, Chen C, Yan B, Zhu L, Chen X, et al. The mechanisms of lysophosphatidylcholine in the development of diseases. Life Sci. 2020;247: 117443.PubMedCrossRef
39.
Zurück zum Zitat Breeur M, Ferrari P, Dossus L, Jenab M, Johansson M, Rinaldi S, et al. Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European prospective investigation into cancer and nutrition. BMC Med. 2022;20:351.PubMedPubMedCentralCrossRef Breeur M, Ferrari P, Dossus L, Jenab M, Johansson M, Rinaldi S, et al. Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European prospective investigation into cancer and nutrition. BMC Med. 2022;20:351.PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Barber MN, Risis S, Yang C, Meikle PJ, Staples M, Febbraio MA, et al. Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoS ONE. 2012;7: e41456.PubMedCrossRef Barber MN, Risis S, Yang C, Meikle PJ, Staples M, Febbraio MA, et al. Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoS ONE. 2012;7: e41456.PubMedCrossRef
41.
Zurück zum Zitat Wang Y, Jiang C-T, Song J-Y, Song Q-Y, Ma J, Wang H-J. Lipidomic profile revealed the association of plasma lysophosphatidylcholines with adolescent obesity. BioMed Res Int. 2019;2019:1382418.PubMedPubMedCentralCrossRef Wang Y, Jiang C-T, Song J-Y, Song Q-Y, Ma J, Wang H-J. Lipidomic profile revealed the association of plasma lysophosphatidylcholines with adolescent obesity. BioMed Res Int. 2019;2019:1382418.PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Floegel A, Stefan N, Yu Z, Mühlenbruch K, Drogan D, Joost H-G, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes. 2013;62:639–48.PubMedPubMedCentralCrossRef Floegel A, Stefan N, Yu Z, Mühlenbruch K, Drogan D, Joost H-G, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes. 2013;62:639–48.PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, He Y, et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol. 2012;8:615.PubMedPubMedCentralCrossRef Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, He Y, et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol. 2012;8:615.PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat van der Veen JN, Kennelly JP, Wan S, Vance JE, Vance DE, Jacobs RL. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochim Biophys Acta Biomembr. 2017;1859:1558–72.PubMedCrossRef van der Veen JN, Kennelly JP, Wan S, Vance JE, Vance DE, Jacobs RL. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochim Biophys Acta Biomembr. 2017;1859:1558–72.PubMedCrossRef
45.
Zurück zum Zitat Wang X, Wang S, Tang X, Zhang A, Grabinski T, Guo Z, et al. Development and evaluation of monoclonal antibodies against phosphatidylethanolamine binding protein 1 in pancreatic cancer patients. J Immunol Methods. 2010;362:151–60.CrossRef Wang X, Wang S, Tang X, Zhang A, Grabinski T, Guo Z, et al. Development and evaluation of monoclonal antibodies against phosphatidylethanolamine binding protein 1 in pancreatic cancer patients. J Immunol Methods. 2010;362:151–60.CrossRef
46.
Zurück zum Zitat Newsom SA, Brozinick JT, Kiseljak-Vassiliades K, Strauss AN, Bacon SD, Kerege AA, et al. Skeletal muscle phosphatidylcholine and phosphatidylethanolamine are related to insulin sensitivity and respond to acute exercise in humans. J Appl Physiol Bethesda Md. 1985;2016(120):1355–63. Newsom SA, Brozinick JT, Kiseljak-Vassiliades K, Strauss AN, Bacon SD, Kerege AA, et al. Skeletal muscle phosphatidylcholine and phosphatidylethanolamine are related to insulin sensitivity and respond to acute exercise in humans. J Appl Physiol Bethesda Md. 1985;2016(120):1355–63.
47.
Zurück zum Zitat Rhee EP, Cheng S, Larson MG, Walford GA, Lewis GD, McCabe E, et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest. 2011;121:1402–11.PubMedPubMedCentralCrossRef Rhee EP, Cheng S, Larson MG, Walford GA, Lewis GD, McCabe E, et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest. 2011;121:1402–11.PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Yuan C, Babic A, Khalaf N, Nowak JA, Brais LK, Rubinson DA, et al. Diabetes, weight change, and pancreatic cancer risk. JAMA Oncol. 2020;6: e202948.PubMedCrossRef Yuan C, Babic A, Khalaf N, Nowak JA, Brais LK, Rubinson DA, et al. Diabetes, weight change, and pancreatic cancer risk. JAMA Oncol. 2020;6: e202948.PubMedCrossRef
49.
Zurück zum Zitat Naudin S, Sampson JN, Moore SC, Stolzenberg-Solomon R. Sources of variability in serum lipidomic measurements and implications for epidemiologic studies. Am J Epidemiol. 2022;191:1926–35.PubMedPubMedCentralCrossRef Naudin S, Sampson JN, Moore SC, Stolzenberg-Solomon R. Sources of variability in serum lipidomic measurements and implications for epidemiologic studies. Am J Epidemiol. 2022;191:1926–35.PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Mayfield J. Diagnosis and classification of diabetes mellitus: new criteria. Am Fam Physician. 1998;58(1355–62):1369–70. Mayfield J. Diagnosis and classification of diabetes mellitus: new criteria. Am Fam Physician. 1998;58(1355–62):1369–70.
51.
Zurück zum Zitat Carrard J, Gallart-Ayala H, Infanger D, Teav T, Wagner J, Knaier R, et al. Metabolic view on human healthspan: a lipidome-wide association study. Metabolites. 2021;11:287.PubMedPubMedCentralCrossRef Carrard J, Gallart-Ayala H, Infanger D, Teav T, Wagner J, Knaier R, et al. Metabolic view on human healthspan: a lipidome-wide association study. Metabolites. 2021;11:287.PubMedPubMedCentralCrossRef
Metadaten
Titel
Lipidomics and pancreatic cancer risk in two prospective studies
verfasst von
Sabine Naudin
Joshua N. Sampson
Steven C. Moore
Demetrius Albanes
Neal D. Freedman
Stephanie J. Weinstein
Rachael Stolzenberg-Solomon
Publikationsdatum
12.05.2023
Verlag
Springer Netherlands
Erschienen in
European Journal of Epidemiology / Ausgabe 7/2023
Print ISSN: 0393-2990
Elektronische ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-023-01014-3

Weitere Artikel der Ausgabe 7/2023

European Journal of Epidemiology 7/2023 Zur Ausgabe